Notably, distinct methodologies for celiac disease serum testing were employed across the two cohorts: the study group underwent testing for anti-tTG IgG, whereas the control group was assessed for EMA IgA and anti-gliadin IgA/IgG, being part of a previous study. This evidence concerns the gene TGM2 and celiac disease.